ProCE Banner Activity

How We Are Integrating New Data Into Relapsed/Refractory Myeloma Treatment

Clinical Thought
Two expert pharmacists provide their insights on optimally managing patients with relapsed/refractory multiple myeloma.

Released: July 29, 2022

Expiration: July 28, 2023

Share

Faculty

Rebecca Gonzalez

Rebecca Gonzalez, PharmD, BCOP

Clinical Pharmacist
Blood and Marrow Transplant/Cellular Immunotherapy
Department of Pharmacy
Moffitt Cancer Center
Tampa, Florida

Donald C. Moore

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP

Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Institute
Charlotte, North Carolina

Provided by

Provided by ProCE, LLC
ProCE Banner

Supporters

Supported by educational grants from

Janssen administered by Scientific Affairs

Karyopharm Therapeutics Inc.

Faculty Disclosure

Primary Author

Rebecca Gonzalez, PharmD, BCOP

Clinical Pharmacist
Blood and Marrow Transplant/Cellular Immunotherapy
Department of Pharmacy
Moffitt Cancer Center
Tampa, Florida

Rebecca Gonzalez, PharmD, BCOP, has no relevant financial relationships to disclose.

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP

Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Institute
Charlotte, North Carolina

Donald C. Moore, PharmD, BCPS, BCOP, DPLA: consultant/advisor/speaker: AstraZeneca, Janssen, Oncopeptides, Pfizer.